Inhibition of DNA Double-Strand Break Repair by the Dual PI3K/mTOR Inhibitor NVP-BEZ235 as a Strategy for Radiosensitization of Glioblastoma

被引:134
作者
del Alcazar, Carlos Rodrigo Gil [1 ]
Hardebeck, Molly Catherine [1 ]
Mukherjee, Bipasha [1 ]
Tomimatsu, Nozomi [1 ]
Gao, Xiaohuan [1 ]
Yan, Jingsheng [2 ]
Xie, Xian-Jin [2 ]
Bachoo, Robert [3 ]
Li, Li [3 ,4 ]
Habib, Amyn A. [3 ,4 ]
Burma, Sandeep [1 ]
机构
[1] Univ Texas SW Med Ctr Dallas, Dept Radiat Oncol, Dallas, TX 75390 USA
[2] Univ Texas SW Med Ctr Dallas, Dept Clin Sci, Dallas, TX 75390 USA
[3] Univ Texas SW Med Ctr Dallas, Dept Neurol & Neurotherapeut, Dallas, TX 75390 USA
[4] VA North Texas Hlth Care Syst, Dallas, TX USA
基金
美国国家航空航天局;
关键词
PHOSPHATIDYLINOSITOL 3-KINASE/MAMMALIAN TARGET; DEPENDENT PROTEIN-KINASE; RAPAMYCIN INHIBITOR; PRECLINICAL EVALUATION; ADJUVANT TEMOZOLOMIDE; DAMAGE RESPONSE; CANCER-CELLS; IN-VIVO; ATM; RADIOTHERAPY;
D O I
10.1158/1078-0432.CCR-13-1607
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Inhibitors of the DNA damage response (DDR) have great potential for radiosensitization of numerous cancers, including glioblastomas, which are extremely radio- and chemoresistant brain tumors, Currently, there are no DNA double-strand break (DSB) repair inhibitors that have been successful in treating glioblastoma. Our laboratory previously demonstrated that the dual phosphoinositide 3-kinase/mTOR inhibitor NVP-BEZ235 can potently inhibit the two central DDR kinases, DNA-dependent protein kinase catalytic subunit (DNA-PKcs) and ataxia-telangiectasia mutated (ATM), in vitro, Here, we tested whether NVP-BEZ235 could also inhibit ATM and DNA-PKcs in tumors in viva and assessed its potential as a radio- and chemosensitizer in preclinical mouse glioblastoma models. Experimental Design: The radiosensitizing effect of NVP-BEZ235 was tested by following tumor growth in subcutaneous and ortho topic glioblastoma models, Tumors were generated using the radioresistant U87-vIII glioma cell line and GBM9 neurospheres in nude mice. These tumors were then treated with ionizing radiation and/or NVP-BEZ235 and analyzed for DNA-PKcs and ATM activation, DSB repair inhibition, and attenuation of growth. Results: NVP-BEZ235 potently inhibited both DNA-PKcs and ATM kinases and attenuated the repair of ionizing radiation-induced DNA damage in tumors. This resulted in striking tumor radiosensitization, which extended the survival of brain tumor-bearing mice. Notably, tumors displayed a higher DSB-load when compared with normal brain tissue. NVP-BEZ235 also sensitized a subset of subcutaneous tumors to temozolomide, a drug routinely used concurrently with ionizing radiation for the treatment of glioblastoma. Conclusions: These results demonstrate that it may be possible to significantly improve glioblastoma therapy by combining ionizing radiation with potent and bioavailable DNA repair inhibitors such as NVP-BEZ235. (C) 2013 AACR.
引用
收藏
页码:1235 / 1248
页数:14
相关论文
共 50 条
[1]   Glioma stem cells promote radioresistance by preferential activation of the DNA damage response [J].
Bao, Shideng ;
Wu, Qiulian ;
McLendon, Roger E. ;
Hao, Yueling ;
Shi, Qing ;
Hjelmeland, Anita B. ;
Dewhirst, Mark W. ;
Bigner, Darell D. ;
Rich, Jeremy N. .
NATURE, 2006, 444 (7120) :756-760
[2]   Replication stress and oxidative damage contribute to aberrant constitutive activation of DNA damage signalling in human gliomas [J].
Bartkova, J. ;
Hamerlik, P. ;
Stockhausen, M-T ;
Ehrmann, J. ;
Hlobilkova, A. ;
Laursen, H. ;
Kalita, O. ;
Kolar, Z. ;
Poulsen, H. S. ;
Broholm, H. ;
Lukas, J. ;
Bartek, J. .
ONCOGENE, 2010, 29 (36) :5095-5102
[3]   Preclinical Evaluation of a Novel ATM Inhibitor, KU59403, In Vitro and In Vivo in p53 Functional and Dysfunctional Models of Human Cancer [J].
Batey, Michael A. ;
Zhao, Yan ;
Kyle, Suzanne ;
Richardson, Caroline ;
Slade, Andrew ;
Martin, Niall M. B. ;
Lau, Alan ;
Newell, David R. ;
Curtin, Nicola J. .
MOLECULAR CANCER THERAPEUTICS, 2013, 12 (06) :959-967
[4]   GENOMIC INSTABILITY IN CANCER Strategies to improve radiotherapy with targeted drugs [J].
Begg, Adrian C. ;
Stewart, Fiona A. ;
Vens, Conchita .
NATURE REVIEWS CANCER, 2011, 11 (04) :239-253
[5]   ATM Kinase Inhibition Preferentially Sensitizes p53-Mutant Glioma to Ionizing Radiation [J].
Biddlestone-Thorpe, Laura ;
Sajjad, Muhammad ;
Rosenberg, Elizabeth ;
Beckta, Jason M. ;
Valerie, Nicholas C. K. ;
Tokarz, Mary ;
Adams, Bret R. ;
Wagner, Alison F. ;
Khalil, Ashraf ;
Gilfor, Donna ;
Golding, Sarah E. ;
Deb, Sumitra ;
Temesi, David G. ;
Lau, Alan ;
O'Connor, Mark J. ;
Choe, Kevin S. ;
Parada, Luis F. ;
Lim, Sang Kyun ;
Mukhopadhyay, Nitai D. ;
Valerie, Kristoffer .
CLINICAL CANCER RESEARCH, 2013, 19 (12) :3189-3200
[6]   Temporally Specified Genetic Ablation of Neurogenesis Impairs Cognitive Recovery after Traumatic Brain Injury [J].
Blaiss, Cory A. ;
Yu, Tzong-Shiue ;
Zhang, Gui ;
Chen, Jian ;
Dimchev, Georgi ;
Parada, Luis F. ;
Powell, Craig M. ;
Kernie, Steven G. .
JOURNAL OF NEUROSCIENCE, 2011, 31 (13) :4906-4916
[7]   Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells [J].
Brachmann, Saskia M. ;
Hofmann, Irmgard ;
Schnell, Christian ;
Fritsch, Christine ;
Wee, Susan ;
Lane, Heidi ;
Wang, Shaowen ;
Garcia-Echeverria, Carlos ;
Maira, Sauveur-Michel .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2009, 106 (52) :22299-22304
[8]   A Versatile Viral System for Expression and Depletion of Proteins in Mammalian Cells [J].
Campeau, Eric ;
Ruhl, Victoria E. ;
Rodier, Francis ;
Smith, Corey L. ;
Rahmberg, Brittany L. ;
Fuss, Jill O. ;
Campisi, Judith ;
Yaswen, Paul ;
Cooper, Priscilla K. ;
Kaufmann, Paul D. .
PLOS ONE, 2009, 4 (08)
[9]   Inhibition of Autophagy as a Strategy to Augment Radiosensitization by the Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235 [J].
Cerniglia, George J. ;
Karar, Jayashree ;
Tyagi, Sonia ;
Christofidou-Solomidou, Melpo ;
Rengan, Ramesh ;
Koumenis, Constantinos ;
Maity, Amit .
MOLECULAR PHARMACOLOGY, 2012, 82 (06) :1230-1240
[10]  
Chanthery YH, 2012, SCI TRANSL MED, V4